Han Na HONG,Jun Hwan KIM,Hyun Ho CHOI,Dohoon KIM,Taewang KIM,Se Woong OH,Moo Young SONG,Jong Gyun KIM
申请号：
US16348249
公开号：
US20190314452A1
申请日:
2017.11.10
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention provides a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. Specifically, the present invention provides a fusion protein comprising a biologically active protein and an FGF21 mutant protein； and a pharmaceutical composition containing the fusion protein, which is effective for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. A pharmaceutical composition of the present invention has the effect of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used as a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.
